Literature DB >> 449278

Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders.

O Kawanami, V J Ferrans, J D Fulmer, R G Crystal.   

Abstract

The topographic distribution, population density, and ultrastructural features of metachromatic cells (mast cells and basophilic leukocytes) were studied in lung biopsies from five control patients and 17 patients with fibrotic lung disorders. The great majority of metachromatic cells were mast cells. The average number of metachromatic cells per square millimeter of tissue section was much larger in patients with fibrotic lung disorders (45.8 +/- 6.5) than in control patients (2.6 +/- 1.6). In control patients, mast cells were most frequently seen in subpleural and perivascular connective tissue. In contrast, the vast majority of mast cells in patients with fibrotic lung disorders was present in thickened, fibrous alveolar septa; mast cells also were found within the alveolar epithelial layer and alveolar lumina. The quantitative distribution of different types of mast cell granules differed in the two groups of patients: granules composed of scrolls were more frequent in control patients, and granules of the combined type (containing mixtures of different components within the same granule) were more frequent in patients with fibrotic lung disorders. Mast cells in the latter patients appeared to migrate through defects in the basement membrane into the epithelial layer and alveolar lumina; mast cells in these areas often showed reduced numbers of granules and disorganized granule content. These changes suggest that pulmonary parenchymal mast cells in fibrotic lung disorders undergo a chronic process of partial degranulation which differs from that found in anaphylaxis; this chronic release of mast cell products may contribute to the continuing alveolar injury and the ventilation-perfusion inequalities observed in the fibrotic lung disorders.

Entities:  

Mesh:

Year:  1979        PMID: 449278

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  60 in total

Review 1.  Tryptase and chymase, markers of distinct types of human mast cells.

Authors:  S S Craig; L B Schwartz
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Mast cells and fibrosis in compartments of lymph nodes of normal, gnotobiotic, and athymic rats.

Authors:  G Sainte-Marie; F S Peng
Journal:  Cell Tissue Res       Date:  1990-07       Impact factor: 5.249

3.  Bronchoalveolar mast cells in sarcoidosis: increased numbers and accentuation of mediator release.

Authors:  K C Flint; K B Leung; B N Hudspith; J Brostoff; F L Pearce; D Geraint-James; N M Johnson
Journal:  Thorax       Date:  1986-02       Impact factor: 9.139

4.  Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia. Cell-matrix patterns.

Authors:  S Peyrol; J F Cordier; J A Grimaud
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

Review 5.  The ultrastructure of human fibrosing alveolitis.

Authors:  J J Coalson
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

Review 6.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

7.  Evaluation of capsular and acapsular strains of S. aureus in an experimental brain abscess model.

Authors:  Nilufer Esen; Gail Wagoner; Napoleon Philips
Journal:  J Neuroimmunol       Date:  2009-11-10       Impact factor: 3.478

Review 8.  Basophils in human disease.

Authors:  E B Mitchell; P W Askenase
Journal:  Clin Rev Allergy       Date:  1983-09

9.  Mast cell and histamine content of human bronchoalveolar lavage fluid.

Authors:  R M Agius; R C Godfrey; S T Holgate
Journal:  Thorax       Date:  1985-10       Impact factor: 9.139

10.  Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.

Authors:  Saman Rasoul; Oscar A Carretero; Hongmei Peng; Maria A Cavasin; Jialong Zhuo; Alicia Sanchez-Mendoza; David R Brigstock; Nour-Eddine Rhaleb
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.